联合检测血清糖类抗原标志物在女性绝经前后卵巢浆液性癌诊断中的价值
|
摘要
目的:探讨联合检测血清糖类抗原标志物在女性绝经前后卵巢浆液性癌诊断中的价值。方法:采用回顾性研究方法,选择2016年8月到至2018年2月在我院肿瘤科进行检测的绝经前后卵巢浆液性癌患者60例(癌变组)与绝经前后健康体检者60例(健康对照组),检测其血清癌胚抗原(carcino-embryonic antigen,CEA)、人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原125(carbohydrate antigen 125,CA125)的水平,并分析其与患者的临床病理特征与随访预后的相关性。结果:癌变组血清CEA、HE4、CA125水平及阳性表达率都均显著高于健康对照组(P<0.05)。在癌变组60例患者中,随着病理分期增加、分化程度的减少、淋巴结转移与死亡情况的发生,血清CEA、HE4、CA125的阳性表达率显著升高,对比差异有统计学意义(P<0.05)。同时在120例人群中,联合诊断为卵巢浆液性癌者54例,联合诊断的敏感性与特异性分别为90.0%和100.0%。结论:绝经前后女性卵巢浆液性癌患者血清糖类抗原标志物-CEA、HE4、CA12水平均呈现高表达,可能作为绝经前后女性卵巢浆液性癌诊断与预后预测的参考指标。
Objective: To investigate the values of combined detection of serum carbohydrate antigen markers in the diagnosis of ovarian serous carcinoma in women before and after menopause. Methods: Used a retrospective study, from August 2016 to February2018 60 patients with ovarian serous carcinoma before and after menopause(canceration group) and 60 healthy subjects before and after menopause(health control group) were selected, the serum levels of CEA, HE4 and CA125 were detected, and their correlation with clinicopathological features and follow-up prognosis was analyzed. Results: The levels of serum CEA, HE4, CA125 and positive expression rate in the canceration group were significantly higher than those in the healthy control group(P<0.05). Among the 60 patients in the carcinogenesis group, with the increase of pathological stage, reduction of differentiation, lymph node metastasis and mortality, the positive expression rate of serum CEA, HE4 and CA125 increased significantly, the difference was statistically significant(P<0.05). In the 120 cases, there were 54 cases of ovarian serous carcinoma were combined, the sensitivity and specificity of combined diagnosis were 90.0%and 100.0%, respectively. Conclusion: The levels of serum carbohydrate antigen markers CEA, HE4 and CA12 in premenopausal and postmenopausal women with ovarian serous carcinoma were all increased, which may serve as a reference index for the diagnosis and prognosis prediction of ovarian serous carcinoma in premenopausal and postmenopausal women.
Objective: To investigate the values of combined detection of serum carbohydrate antigen markers in the diagnosis of ovarian serous carcinoma in women before and after menopause. Methods: Used a retrospective study, from August 2016 to February2018 60 patients with ovarian serous carcinoma before and after menopause(canceration group) and 60 healthy subjects before and after menopause(health control group) were selected, the serum levels of CEA, HE4 and CA125 were detected, and their correlation with clinicopathological features and follow-up prognosis was analyzed. Results: The levels of serum CEA, HE4, CA125 and positive expression rate in the canceration group were significantly higher than those in the healthy control group(P<0.05). Among the 60 patients in the carcinogenesis group, with the increase of pathological stage, reduction of differentiation, lymph node metastasis and mortality, the positive expression rate of serum CEA, HE4 and CA125 increased significantly, the difference was statistically significant(P<0.05). In the 120 cases, there were 54 cases of ovarian serous carcinoma were combined, the sensitivity and specificity of combined diagnosis were 90.0%and 100.0%, respectively. Conclusion: The levels of serum carbohydrate antigen markers CEA, HE4 and CA12 in premenopausal and postmenopausal women with ovarian serous carcinoma were all increased, which may serve as a reference index for the diagnosis and prognosis prediction of ovarian serous carcinoma in premenopausal and postmenopausal women.
引文
[1]Bednarska K,Król E,Gowacka E,et al.Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer[J].Medicine(Baltimore),2018,97(12):e0180
[2]Escobar-Morreale HF.Polycystic ovary syndrome:definition,aetiology,diagnosis and treatment[J].Nat Rev Endocrinol,2018,14(5):270-284
[3]Sallum LF,Andrade L,Bastos Eloy da Costa L,et al.BRCA1,Ki67,andβ-Catenin Immunoexpression Is Not Related to Differentiation,Platinum Response,or Prognosis in Women With Low-and High-Grade Serous Ovarian Carcinoma[J].Int J Gynecol Cancer,2018,28(3):437-447
[4]Ellis E,Gibson-Helm M,Boyle JA.Polycystic ovary syndrome in Central Australia:Diagnosis and screening of cardiometabolic risk and emotional wellbeing[J].Aust J Gen Pract,2018,4(4):227-232
[5]Kessous R,Octeau D,Klein K,et al.Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer[J].Gynecol Oncol,2018,148(3):553-558
[6]Li Y,Ruan X,Wang H,et al.Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J].Fertil Steril,2018,109(4):720-727
[7]Nakamura K,Nakayama K,Ishikawa M,et al.Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples[J].Oncol Lett,2018,16(1):189-194
[8]Paramonova NB,Kogan EA,Kolotovkina AV,et al.The morphological and molecular biological signs of impaired endometrial receptivity in infertility in women suffering from external genital endometriosis[J].Arkh Patol,2018,80(3):11-18
[9]Heshmati J,Omani-Samani R,Vesali S,et al.The Effects of Supplementation with Chromium on Insulin Resistance Indices in Women with Polycystic Ovarian Syndrome:A Systematic Review and Meta-Analysis of Randomized Clinical Trials[J].Horm Metab Res,2018,50(3):193-200
[10]Song S E,Choi P,Kim J H,et al.Diagnostic Value of Carcinoembryonic Antigen in Ascites for Colorectal Cancer with Peritoneal Carcinomatosis[J].2018,71(6):332-337
[11]Kong Y,Yin J,Fu Y,et al.Suppression of Elk1 inhibits thyroid cancer progression by mediating PTEN expression[J].Oncol Rep,2018,40(3):1769-1776
[12]Acharya A,Markar SR,Matar M,et al.Use of Tumor Markers in Gastrointestinal Cancers:Surgeon Perceptions and Cost-Benefit Trade-Off Analysis[J].Ann Surg Oncol,2017,24(5):1165-1173
[13]Suo HB,Zhang KC,Zhao J.MiR-200a promotes cell invasion and migration of ovarian carcinoma by targeting PTEN[J].Eur Rev Med Pharmacol Sci,2018,22(13):4080-4089
[14]Kumarendran B,O'Reilly MW,Manolopoulos KN,et al.Polycystic ovary syndrome,androgen excess,and the risk of nonalcoholic fatty liver disease in women:A longitudinal study based on a United Kingdom primary care database[J].PLoS Med,2018,15(3):e1002542
[15]Morishita M,Endo T,Baba T,et al.Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance[J].J Ovarian Res,2018,11(1):24
[16]Yan H,Zhang J,Wen J,et al.CDC42 controls the activation of primordial follicles by regulating PI3K signaling in mouse oocytes[J].BMC Biol,2018,16(1):73
[17]Gong L,Zhang W,Yuan Y,et al.miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN[J].Oncol Lett,2018,16(1):984-990
[18]Liu DT,Yao HR,Li YY,et al.MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKTsignaling pathway[J].Oncol Lett,2018,16(1):559-565
[19]Lazaridou S,Dinas K,Tziomalos K.Prevalence,pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome[J].Hormones(Athens),2017,16(4):373-380
[20]Li G,Huang W,Zhang L,et al.A prospective cohort study of earlypregnancy risk factors for gestational diabetes in polycystic ovarian syndrome[J].Diabetes Metab Res Rev,2018,3(7):e3003
[21]Santotoribio J D,Garciade l T A,Ca觡avatesolano C,et al.Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors[J].European Journal of Gynaecological Oncology,2016:26-29
[22]Yang L,Chen L,Lu X,et al.Peri-ovarian adipose tissue contributes to intraovarian control during folliculogenesis in mice[J].Reproduction,2018,156(2):133-144
[23]Mueller JJ,Schlappe BA,Kumar R,et al.Massively parallel sequencing analysis of mucinous ovarian carcinomas:genomic profiling and differential diagnoses[J].Gynecol Oncol,2018,150(1):127-135
[24]Mukuda N,Fujii S,Inoue C,et al.Bilateral Ovarian Tumors on MRI:How Should We Differentiate the Lesions?[J].Yonago Acta Med,2018,61(2):110-116
[25]Choi JH,Sohn GS,Chay DB,et al.Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas[J].Obstet Gynecol Sci,2018,61(3):344-351
[26]Palomar Mu觡oz A,Cordero García JM,Talavera Rubio MDP,et al.Value of[18F]FDG-PET/CT and CA125,serum levels and kinetic parameters,in early detection of ovarian cancer recurrence:Influence of histological subtypes and tumor stages[J].Medicine(Baltimore),2018,97(17):e0098
[27]El Sherbini MA,Mansour AA,Sallam MM,et al.KLK10 exon 3 unmethylated PCR product concentration:a new potential early diagnostic marker in ovarian cancer?-A pilot study[J].J Ovarian Res,2018,11(1):32
[28]Zhang W,Wang L,Xin Z.Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer[J].Medicine(Baltimore),2018,97(16):e0358
[29]Sallum LF,Andrade L,Ramalho S,et al.WT1,p53 and p16 expression in the diagnosis of low-and high-grade serous ovarian carcinomas and their relation to prognosis[J].Oncotarget,2018,9(22):15818-15827
[30]Han C,Bellone S,Siegel ER,et al.A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma[J].Gynecol Oncol,2018,149(3):585-591
[2]Escobar-Morreale HF.Polycystic ovary syndrome:definition,aetiology,diagnosis and treatment[J].Nat Rev Endocrinol,2018,14(5):270-284
[3]Sallum LF,Andrade L,Bastos Eloy da Costa L,et al.BRCA1,Ki67,andβ-Catenin Immunoexpression Is Not Related to Differentiation,Platinum Response,or Prognosis in Women With Low-and High-Grade Serous Ovarian Carcinoma[J].Int J Gynecol Cancer,2018,28(3):437-447
[4]Ellis E,Gibson-Helm M,Boyle JA.Polycystic ovary syndrome in Central Australia:Diagnosis and screening of cardiometabolic risk and emotional wellbeing[J].Aust J Gen Pract,2018,4(4):227-232
[5]Kessous R,Octeau D,Klein K,et al.Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer[J].Gynecol Oncol,2018,148(3):553-558
[6]Li Y,Ruan X,Wang H,et al.Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J].Fertil Steril,2018,109(4):720-727
[7]Nakamura K,Nakayama K,Ishikawa M,et al.Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples[J].Oncol Lett,2018,16(1):189-194
[8]Paramonova NB,Kogan EA,Kolotovkina AV,et al.The morphological and molecular biological signs of impaired endometrial receptivity in infertility in women suffering from external genital endometriosis[J].Arkh Patol,2018,80(3):11-18
[9]Heshmati J,Omani-Samani R,Vesali S,et al.The Effects of Supplementation with Chromium on Insulin Resistance Indices in Women with Polycystic Ovarian Syndrome:A Systematic Review and Meta-Analysis of Randomized Clinical Trials[J].Horm Metab Res,2018,50(3):193-200
[10]Song S E,Choi P,Kim J H,et al.Diagnostic Value of Carcinoembryonic Antigen in Ascites for Colorectal Cancer with Peritoneal Carcinomatosis[J].2018,71(6):332-337
[11]Kong Y,Yin J,Fu Y,et al.Suppression of Elk1 inhibits thyroid cancer progression by mediating PTEN expression[J].Oncol Rep,2018,40(3):1769-1776
[12]Acharya A,Markar SR,Matar M,et al.Use of Tumor Markers in Gastrointestinal Cancers:Surgeon Perceptions and Cost-Benefit Trade-Off Analysis[J].Ann Surg Oncol,2017,24(5):1165-1173
[13]Suo HB,Zhang KC,Zhao J.MiR-200a promotes cell invasion and migration of ovarian carcinoma by targeting PTEN[J].Eur Rev Med Pharmacol Sci,2018,22(13):4080-4089
[14]Kumarendran B,O'Reilly MW,Manolopoulos KN,et al.Polycystic ovary syndrome,androgen excess,and the risk of nonalcoholic fatty liver disease in women:A longitudinal study based on a United Kingdom primary care database[J].PLoS Med,2018,15(3):e1002542
[15]Morishita M,Endo T,Baba T,et al.Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance[J].J Ovarian Res,2018,11(1):24
[16]Yan H,Zhang J,Wen J,et al.CDC42 controls the activation of primordial follicles by regulating PI3K signaling in mouse oocytes[J].BMC Biol,2018,16(1):73
[17]Gong L,Zhang W,Yuan Y,et al.miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN[J].Oncol Lett,2018,16(1):984-990
[18]Liu DT,Yao HR,Li YY,et al.MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKTsignaling pathway[J].Oncol Lett,2018,16(1):559-565
[19]Lazaridou S,Dinas K,Tziomalos K.Prevalence,pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome[J].Hormones(Athens),2017,16(4):373-380
[20]Li G,Huang W,Zhang L,et al.A prospective cohort study of earlypregnancy risk factors for gestational diabetes in polycystic ovarian syndrome[J].Diabetes Metab Res Rev,2018,3(7):e3003
[21]Santotoribio J D,Garciade l T A,Ca觡avatesolano C,et al.Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors[J].European Journal of Gynaecological Oncology,2016:26-29
[22]Yang L,Chen L,Lu X,et al.Peri-ovarian adipose tissue contributes to intraovarian control during folliculogenesis in mice[J].Reproduction,2018,156(2):133-144
[23]Mueller JJ,Schlappe BA,Kumar R,et al.Massively parallel sequencing analysis of mucinous ovarian carcinomas:genomic profiling and differential diagnoses[J].Gynecol Oncol,2018,150(1):127-135
[24]Mukuda N,Fujii S,Inoue C,et al.Bilateral Ovarian Tumors on MRI:How Should We Differentiate the Lesions?[J].Yonago Acta Med,2018,61(2):110-116
[25]Choi JH,Sohn GS,Chay DB,et al.Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas[J].Obstet Gynecol Sci,2018,61(3):344-351
[26]Palomar Mu觡oz A,Cordero García JM,Talavera Rubio MDP,et al.Value of[18F]FDG-PET/CT and CA125,serum levels and kinetic parameters,in early detection of ovarian cancer recurrence:Influence of histological subtypes and tumor stages[J].Medicine(Baltimore),2018,97(17):e0098
[27]El Sherbini MA,Mansour AA,Sallam MM,et al.KLK10 exon 3 unmethylated PCR product concentration:a new potential early diagnostic marker in ovarian cancer?-A pilot study[J].J Ovarian Res,2018,11(1):32
[28]Zhang W,Wang L,Xin Z.Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer[J].Medicine(Baltimore),2018,97(16):e0358
[29]Sallum LF,Andrade L,Ramalho S,et al.WT1,p53 and p16 expression in the diagnosis of low-and high-grade serous ovarian carcinomas and their relation to prognosis[J].Oncotarget,2018,9(22):15818-15827
[30]Han C,Bellone S,Siegel ER,et al.A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma[J].Gynecol Oncol,2018,149(3):585-591
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |